Table 2.
Ophthalmologic conditions marketed by “cell therapy” clinics.
| Marketed Condition | Number of Businesses |
|---|---|
| Macular degeneration | 35 |
| Optic neuritis | 18 |
| Retinitis pigmentosa | 17 |
| Diabetic retinopathy | 16 |
| Glaucoma | 14 |
| Optic neuropathy* | 13 |
| Retinal detachment | 8 |
| Dry eye | 7 |
| Stargardt’s macular dystrophy | 4 |
| Retinal degeneration | 3 |
| Macular hole | 2 |
| Blindness | 2 |
| Central retinal vein occlusion/retinal vascular occlusion | 3 |
| Plaquenil toxicity | 2 |
| Corneal diseases | 2 |
| Limbal stem cell deficiency | 2 |
| Corneal ulcers | 2 |
| Retinal micro hemorrhage | 1 |
| Myopic macular degeneration | 1 |
| Ischemic retinopathy | 1 |
| Retinitis | 1 |
| Ophthalmology | 1 |
| Stevens-Johnson syndrome | 1 |
| Trauma | 1 |
Optic neuropathy includes optic nerve atrophy, Leber’s hereditary optic neuropathy, and optic nerve injury.